<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03611348</url>
  </required_header>
  <id_info>
    <org_study_id>VIT.LT2018</org_study_id>
    <nct_id>NCT03611348</nct_id>
  </id_info>
  <brief_title>Microneedling and Latanoprost in Acrofacial Vitiligo</brief_title>
  <official_title>Effectiveness of Microneedling and Topical Latanoprost in Treatment of Acrofacial Vitiligo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare efficacy of topical latanoprost preceded by microneedling versus topical&#xD;
      latanoprost alone in treatment of acrofacial vitiligo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      patients meeting inclusion and exclusion criteria presented to Dermatology Outpatient Clinic,&#xD;
      Sohag University Hospital will be enrolled in the study after obtaining a written consent&#xD;
      from them. Full history will be obtained and meticulous examination will be carried out.&#xD;
      Patients will be randomly divided into 2 groups, one group will receive topical latanoprost&#xD;
      with microneedling, and the other one will receive topical latabnoprost alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">September 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in VASI score</measure>
    <time_frame>6 months</time_frame>
    <description>VASI score: The percentage of vitiligo involvement is calculated in terms of hand units. One hand unit is approximately equivalent to 1% of the total body surface area. The degree of pigmentation is estimated to the nearest of one of the following percentages:&#xD;
100% - complete depigmentation, no pigment is present&#xD;
90% - specks of pigment present&#xD;
75% - depigmented area exceeds the pigmented area&#xD;
50% - pigmented and depigmented areas are equal&#xD;
25% - pigmented area exceeds depigmented area&#xD;
10% - only specks of depigmentation present. The VASI for each body region is determined by the product of the area of vitiligo in hand units and the extent of depigmentation within each hand unit measured patch.&#xD;
Total body VASI = S All body sites [Hand Units] x [Residual depigmentation]. (Feily et al., 2014).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Vitiligo</condition>
  <arm_group>
    <arm_group_label>Microneedling + latanoprost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient will receive topical application of latanoprost 0.005% eye drops solution twice daily for 3 months preceded by microneeding in sessions by dermapen every 2 weeks for 3 months (totally 6 sessions).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>latanoprost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will receive topical application of latanoprost 0.005% eye drops solution only twice daily for 3 months (active control side).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost</intervention_name>
    <description>Topical application of latanoprost 0.005% eye drops solution only twice daily for 3 months.&#xD;
To apply latanoprost solution, one drop of the solution will be distributed over 1cm2 of depigmented skin. Side effects will be recorded.</description>
    <arm_group_label>Microneedling + latanoprost</arm_group_label>
    <arm_group_label>latanoprost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microneedling</intervention_name>
    <description>A superficial micro-needling technique will be done in millimeters according to depth of skin. The vitiliginous area and a thin surrounding rim (about 2 mm) will be subjected to micro-needling with dermapen. The depth of abrasion will be guided by the depth adjustor according to depth of skin on the affected area. This will be followed by the appearance of multiple, tiny, punctate, bleeding points</description>
    <arm_group_label>Microneedling + latanoprost</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Acrofacial stable vitiligo for 6 months duration (without new lesions appearance or&#xD;
        change in size of the existing lesions).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of scar formation.&#xD;
&#xD;
          -  Patients with systemic diseases (diabetes, bleeding disorders, chronic renal diseases,&#xD;
             chronic liver diseases, asthma and hypertension).&#xD;
&#xD;
          -  Patients who are receiving chemotherapy or radiotherapy.&#xD;
&#xD;
          -  Pregnant and lactating females.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramadan Saleh, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sohag University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Noreen IS Abdelghany, M.B.B.Ch.</last_name>
    <phone>1093744655</phone>
    <phone_ext>+20</phone_ext>
    <email>noreen.ismael@yahoo.com</email>
  </overall_contact>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 26, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>August 26, 2018</last_update_submitted>
  <last_update_submitted_qc>August 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Noreen Ismail AbdelGhani Ahmed</investigator_full_name>
    <investigator_title>resident at general administration of medical affairs</investigator_title>
  </responsible_party>
  <keyword>acrofacal vitiligo, latanoprost, microneedling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Share study proposal, patients and methods, results.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>1 year</ipd_time_frame>
    <ipd_access_criteria>Permission obtained from study director</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

